Stay in the know with VTCRC news & happenings. Sign up for our email list.

Creating impact and partnerships in life sciences @ the VTCRC → Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company, located at the research park, is utilizing its LANCE® Advanced A.I. platform to develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease (CD).

“Entering this partnership with the Icahn School of Medicine at Mount Sinai highlights our ability to pursue innovative clinical and translational studies that build on our pioneering immunometabolism franchise in autoimmune diseases,” said Dr. Josep Bassaganya-Riera, Chairman, President, and CEO of Landos.

Read full press release

Inquire about the research park’s #SpaceWithPurpose